Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares to a record high.
The Waltham, Massachusetts-based company’s shares more than doubled to $77.
Source: Reuters
Filed Under: Drug Discovery
